These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 8627061)

  • 1. Phase I trial of interferon alfa-n3 in early-stage human immunodeficiency virus type 1 disease: evidence for drug safety, tolerance, and antiviral activity.
    Skillman DR; Malone JL; Decker CF; Wagner KF; Mapou RL; Liao MJ; Testa D; Meltzer MS
    J Infect Dis; 1996 May; 173(5):1107-14. PubMed ID: 8627061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of efficacy of low dose oral interferon alfa in symptomatic HIV-1 infection: a randomised, double blind, placebo controlled trial.
    Katabira ET; Sewankambo NK; Mugerwa RD; Belsey EM; Mubiru FX; Othieno C; Kataaha P; Karam M; Youle M; Perriens JH; Lange JM
    Sex Transm Infect; 1998 Aug; 74(4):265-70. PubMed ID: 9924466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of condylomata acuminata with pegylated interferon alfa-2b in HIV-infected patients.
    Brockmeyer NH; Poffhoff A; Bader A; Hochdorfer B; Schlottmann R; Rasokat H; Altmeyer P; Kreuter A
    Eur J Med Res; 2006 Jan; 11(1):27-32. PubMed ID: 16504957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergy, activity and tolerability of zidovudine and interferon-alpha in patients with symptomatic HIV-1 infection: AIDS Clincal Trial Group 068.
    Mildvan D; Bassiakos Y; Zucker ML; Hyslop N; Krown SE; Sacks HS; Zachary J; Paredes J; Fessel WJ; Rhame F; Kramer F; Fischl MA; Poiesz B; Wood K; Ruprecht RM; Kim J; Grossberg SE; Kasdan P; Bergé P; Marshak A; Pettinelli C
    Antivir Ther; 1996 Apr; 1(2):77-88. PubMed ID: 11321183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuropsychological effects of Interferon Alfa-n3 treatment in asymptomatic human immunodeficiency virus-1-infected individuals.
    Mapou RL; Law WA; Wagner K; Malone JL; Skillman DR
    J Neuropsychiatry Clin Neurosci; 1996; 8(1):74-81. PubMed ID: 8845705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.
    Chung RT; Andersen J; Volberding P; Robbins GK; Liu T; Sherman KE; Peters MG; Koziel MJ; Bhan AK; Alston B; Colquhoun D; Nevin T; Harb G; van der Horst C;
    N Engl J Med; 2004 Jul; 351(5):451-9. PubMed ID: 15282352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon-alpha neutralizing antibodies in HIV and chronic HCV patients treated with natural-source human leukocyte-derived interferon-alpha n3.
    Zhao XX; Hua J; Smith T; Ferencz-Biro K; Liao MJ; Rashidbaigi A
    Hum Antibodies; 1997; 8(3):129-36. PubMed ID: 9322083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiretrovirals plus immunomodulators: didanosine/interferon-alpha combination shows promise.
    Folkers G
    NIAID AIDS Agenda; 1996 Jun; ():8-9. PubMed ID: 11363810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous low-dose interferon-alpha therapy for HIV-related immune thrombocytopenic purpura.
    Northfelt DW; Charlebois ED; Mirda MI; Child C; Kaplan LD; Abrams DI
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Jan; 8(1):45-50. PubMed ID: 8548345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon-alpha in patients with asymptomatic human immunodeficiency virus (HIV) infection. A randomized, placebo-controlled trial.
    Lane HC; Davey V; Kovacs JA; Feinberg J; Metcalf JA; Herpin B; Walker R; Deyton L; Davey RT; Falloon J
    Ann Intern Med; 1990 Jun; 112(11):805-11. PubMed ID: 1971503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of an induction dose of pegylated interferon alpha-2a on early hepatitis C virus kinetics in HIV/HCV co-infected patients: the CORAL-1 multicentre pilot study.
    Tural C; Solà R; Rubio R; Santín M; Planas R; Quereda C; Berenguer J; Montes-Ramírez M; Clotet B;
    J Viral Hepat; 2007 Oct; 14(10):704-13. PubMed ID: 17875005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
    Bazinet M; Pântea V; Cebotarescu V; Cojuhari L; Jimbei P; Albrecht J; Schmid P; Le Gal F; Gordien E; Krawczyk A; Mijočević H; Karimzadeh H; Roggendorf M; Vaillant A
    Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):877-889. PubMed ID: 28964701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term Treatment With Interferon Alfa Diminishes Expression of HIV-1 and Reduces CD4+ T-Cell Activation in Patients Coinfected With HIV and Hepatitis C Virus and Receiving Antiretroviral Therapy.
    Morón-López S; Gómez-Mora E; Salgado M; Ouchi D; Puertas MC; Urrea V; Navarro J; Jou A; Pérez M; Tural C; Clotet B; Montaner LJ; Blanco J; Crespo M; Martinez-Picado J
    J Infect Dis; 2016 Mar; 213(6):1008-12. PubMed ID: 26525407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hematologic toxicity associated with interferon-based hepatitis C therapy in HIV type 1-coinfected subjects.
    Behler CM; Vittinghoff E; Lin F; Chung RT; Peters MG; Robbins GK; Volberding PA
    Clin Infect Dis; 2007 May; 44(10):1375-83. PubMed ID: 17443478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of pegylated interferon alpha-2a therapy for chronic hepatitis C in HIV-infected patients with haemophilia.
    Zhang RF; Sun HQ; Huang Q; Wang JR; Zhang XX; Liu XN; Ma Q; Lu HZ
    Haemophilia; 2010 May; 16(3):502-7. PubMed ID: 20028427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study of interferon-alpha 2b in combination with interleukin-2 in patients with human immunodeficiency virus infection.
    Schnittman SM; Vogel S; Baseler M; Lane HC; Davey RT
    J Infect Dis; 1994 May; 169(5):981-9. PubMed ID: 7909550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impaired antiviral response in human hepatoma cells.
    Keskinen P; Nyqvist M; Sareneva T; Pirhonen J; Melén K; Julkunen I
    Virology; 1999 Oct; 263(2):364-75. PubMed ID: 10544109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early antiviral treatment of hepatitis C virus recurrence after liver transplantation in HIV-infected patients.
    Castells L; Esteban JI; Bilbao I; Vargas V; Allende H; Ribera E; Piron M; Sauleda S; Len O; Pahissa A; Esteban R; Guardia J; Margarit C
    Antivir Ther; 2006; 11(8):1061-70. PubMed ID: 17302376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose IFN-alpha monotherapy in treatment-naive individuals with HIV-1 infection: evidence of potent suppression of viral replication.
    Hatzakis A; Gargalianos P; Kiosses V; Lazanas M; Sypsa V; Anastassopoulou C; Vigklis V; Sambatakou H; Botsi C; Paraskevis D; Stalgis C
    J Interferon Cytokine Res; 2001 Oct; 21(10):861-9. PubMed ID: 11710999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy.
    Rodríguez-Torres M; Rodríguez-Orengo JF; Ríos-Bedoya CF; Fernández-Carbia A; González-Lassalle E; Salgado-Mercado R; Marxuach-Cuétara AM
    J Clin Virol; 2007 Jan; 38(1):32-8. PubMed ID: 17064957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.